0.5573

4.24% -0.0247

After Hours: .56 0.0027 +0.48%

Sangamo Therapeutics Inc (SGMO)

Overview News Price History Option Chain Financials Discussions Forecast

Sangamo Therapeutics Inc stock is traded at $0.5573, with a volume of 7.91M. It is down -4.24% in the last 24 hours and up +17.75% over the past month. Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Previous Close:

$0.582

Open:

$0.5999

24h Volume:

7.91M

Relative Volume:

1.20

Market Cap:

$126.46M

Revenue:

$52.29M

Net Income/Loss:

$-134.84M

P/E Ratio:

-0.7431

EPS:

-0.75

Net Cash Flow:

$-117.11M

1W Performance:

+13.48%

1M Performance:

+17.75%

6M Performance:

-78.81%

1Y Performance:

+31.62%

1-Day Range:

$0.541

$0.609

1-Week Range:

$0.412

$0.609

52-Week Range:

$0.304

$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name

Sangamo Therapeutics Inc

Sector

Healthcare (1170)

Industry

Biotechnology (661)

Phone

(510) 970-6000

Address

501 CANAL BLVD., RICHMOND, CA

Employee

183

Twitter

@sangamotx

Next Earnings Date

2025-05-02

Latest SEC Filings

SGMO's Discussions on Twitter

Compare SGMO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SGMO Sangamo Therapeutics Inc	0.5573	126.46M	52.29M	-134.84M	-117.11M	-0.75
VRTX Vertex Pharmaceuticals Inc	443.40	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	521.00	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	318.25	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	560.04	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	254.49	28.51B	3.81B	-644.79M	-669.77M	-6.24

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-13-24	Upgrade	Truist	Hold → Buy
Dec-10-24	Reiterated	H.C. Wainwright	Buy
Nov-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Apr-28-23	Downgrade	BofA Securities	Neutral → Underperform
Feb-27-23	Upgrade	Wedbush	Neutral → Outperform
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral
Jun-13-22	Resumed	Wedbush	Neutral
May-04-21	Initiated	RBC Capital Mkts	Outperform
Jan-07-21	Resumed	Guggenheim	Neutral
Jan-06-21	Initiated	Stifel	Hold
Dec-16-20	Resumed	H.C. Wainwright	Buy
Sep-08-20	Initiated	BofA Securities	Buy
Jul-07-20	Initiated	SunTrust	Buy
Aug-26-19	Initiated	H.C. Wainwright	Buy
Nov-14-18	Downgrade	JP Morgan	Overweight → Neutral
Nov-09-18	Downgrade	Guggenheim	Buy → Neutral
Oct-10-18	Initiated	Guggenheim	Buy
Jun-20-18	Initiated	BofA/Merrill	Buy
Nov-15-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-22-17	Resumed	Jefferies	Buy
Nov-01-16	Downgrade	Wedbush	Outperform → Neutral
Oct-19-16	Downgrade	Piper Jaffray	Overweight → Neutral
Dec-04-15	Initiated	Wells Fargo	Outperform
Oct-23-15	Resumed	Jefferies	Buy
May-03-13	Initiated	BioLogic Equity Research	Sell
Feb-23-11	Reiterated	JMP Securities	Mkt Outperform
Jul-29-10	Reiterated	Wedbush	Outperform
Oct-19-09	Initiated	Brean Murray	Sell
Oct-07-09	Reiterated	Leerink Swann	Outperform
Aug-25-09	Reiterated	JMP Securities	Mkt Outperform

View All

Sangamo Therapeutics Inc Stock (SGMO) Latest News

Jun 16, 2025

Sangamo Biosciences Approves Amendments to Equity Plan - TipRanks

Jun 16, 2025

Treg Cell-Based Therapies Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Rapa Therapeutics, Orca Bio, Caladrius Biosciences, Sangamo Therapeut - The Globe and Mail

Jun 16, 2025

Jun 11, 2025

Certain Warrants of Sangamo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2025. - MarketScreener

Jun 11, 2025

Jun 09, 2025

H.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO) - MSN

Jun 09, 2025

Jun 06, 2025

Two Sigma Investments LP Acquires 698,296 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World

Jun 06, 2025

Jun 01, 2025

10 Promising Biotech Stocks to Invest in (June 2025) - Securities.io

Jun 01, 2025

May 30, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

May 30, 2025

May 29, 2025

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - Zenopa

May 29, 2025

May 27, 2025

Sangamo Therapeutics’ SWOT analysis: genomic medicine firm faces cash crunch - Investing.com

May 27, 2025

May 26, 2025

Lazard Asset Management LLC Takes Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World

May 26, 2025

May 24, 2025

Captrust Financial Advisors Makes New $30,000 Investment in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World

May 24, 2025

May 22, 2025

StockNews.com Initiates Coverage on Sangamo Therapeutics (NASDAQ:SGMO) - Defense World

May 22, 2025

May 16, 2025

Barclays Issues Pessimistic Forecast for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price - Defense World

May 16, 2025

May 15, 2025

Sangamo Biosciences’ Earnings Call: Progress Amid Challenges - TipRanks

May 15, 2025

May 14, 2025

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - MSN

May 14, 2025

Barclays Updates Price Target for Sangamo Therapeutics (SGMO) | SGMO Stock News - GuruFocus

May 14, 2025